The product is priced at 95% below the brand-name cost. Ease of adoption. The product is FDA-designated as interchangeable and supported by innovative prescriber and patient engagement programs to ...
AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and completing the VOLITE skin quality aesthetics trial to bolster its ...
Investors pummeled AbbVieABBV stock Wednesday after the company delivered a fourth-quarter sales beat that came largely on the back of still-declining Humira sales. Once key to AbbVie's top line, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results